CFDE Data Portal | Search LOC101929494

	Label	Description
	LOC101929494 Gene (Entity type)	ENSG00000276170 - uncharacterized LOC101929494
	GSE162892 ISOX 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE133933 fibulin-3 knockdown 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE161897 MBNL knockout 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE221329 ERK BRAF inhibition thyroid gland 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182710 Drp1 TFAM overexpression 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146612 amiodarone 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC101929494

ENSG00000276170 - uncharacterized LOC101929494

GSE162892 ISOX 3 v 0 human dn

A Gene Set from LINCS

GSE193993 SSTR2 knockout 5 v 3 human dn

A Gene Set from LINCS

GSE133933 fibulin-3 knockdown 0 v 3 human up

A Gene Set from LINCS

GSE161897 MBNL knockout 2 v 1 human dn

A Gene Set from LINCS

GSE221329 ERK BRAF inhibition thyroid gland 1 v 5 human dn

A Gene Set from LINCS

GSE182710 Drp1 TFAM overexpression 1 v 2 human dn

A Gene Set from LINCS

GSE146612 amiodarone 2 v 3 human up

A Gene Set from LINCS

GSE239844 crizotinib 8 v 9 human dn

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 4 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.